IGF2BP3–FZD1/7 Axis Drives Carboplatin Resistance in Triple-Negative Breast Cancer

Study Background and Research Question

Triple-negative breast cancer (TNBC), defined by the absence of estrogen receptor, progesterone receptor, and HER2 expression, is an aggressive cancer subtype with limited therapeutic options. Conventional chemotherapy, particularly with platinum-based agents such as carboplatin, remains a mainstay for TNBC management. However, the emergence of chemoresistance, often mediated by cancer stem-like cells (CSCs), curtails treatment efficacy and leads to tumor recurrence. A growing body of research points to the centrality of RNA modifications—especially N6-methyladenosine (m6A)—in regulating CSC plasticity and chemoresistance, but the precise molecular regulators within TNBC-CSCs remain incompletely defined. Addressing this knowledge gap, the reference study (Cai et al., 2025) interrogates the mechanistic underpinnings of carboplatin resistance in TNBC, focusing on the role of m6A readers in CSC maintenance and drug response.

Key Innovation from the Reference Study

The study by Cai et al. introduces a paradigm-shifting discovery: the m6A reader IGF2BP3 is enriched in TNBC-CSCs, where it directly binds and stabilizes Frizzled class receptors FZD1 and FZD7 transcripts in an m6A-dependent manner. This stabilization promotes the activation of the β-catenin pathway, which in turn enhances stem-like characteristics and drives resistance to carboplatin. Importantly, the research delineates the IGF2BP3–FZD1/7 axis as a critical regulatory node for CSC maintenance and homologous recombination repair capacity. Pharmacological disruption of this axis—via small molecule inhibition of FZD1/7—restores sensitivity to carboplatin, providing a compelling molecular rationale for combinatorial targeting strategies in TNBC.

Methods and Experimental Design Insights

The authors integrated transcriptomic analyses of TCGA-BRCA datasets with functional validation using patient-derived TNBC cells and established models. Fluorescence-activated cell sorting (FACS) was employed to isolate CSC-enriched populations. IGF2BP3 expression was manipulated via RNA interference, and the impact on stemness was assessed through sphere formation, ALDH activity, and EMT marker expression. High-resolution mapping of IGF2BP3 binding sites on FZD1/7 mRNAs was performed using ultraviolet crosslinking and immunoprecipitation (CLIP). m6A dependency was verified by modulating core methyltransferase RBM15. Drug synergy and resistance phenotypes were evaluated using cell viability assays, combination index analysis, and assessment of homologous recombination repair via RAD51 foci quantification. The small molecule Fz7-21 was used to pharmacologically inhibit FZD1/7, both alone and in combination with carboplatin, to determine effects on CSC viability and chemoresistance.

Protocol Parameters

• CSC Enrichment: FACS isolation of CD24−/CD44+ TNBC cells; further ALDHhigh gating for stemness characterization.
• IGF2BP3 Knockdown: siRNA or shRNA transfection; confirmation by qPCR and immunoblotting; functional assays conducted 48–72 h post-knockdown.
• m6A Dependency: RBM15 knockdown to assess impact on FZD1/7 methylation and IGF2BP3 binding.
• Drug Treatment: Carboplatin and/or Fz7-21 administered at literature-backed IC50 concentrations; combinatorial protocols guided by viability and apoptosis endpoints.
• Homologous Recombination Repair Assessment: Quantification of RAD51 foci post-drug exposure to determine DNA repair capacity.

Core Findings and Why They Matter

The central findings from Cai et al. (2025) establish IGF2BP3 as a dominant m6A reader in TNBC-CSCs, with several key mechanistic and translational implications:

• IGF2BP3 is highly enriched in CSC populations, as demonstrated by both transcriptomic and functional assays.
• IGF2BP3 directly binds the 3′ UTRs of FZD1/7 mRNAs in an m6A-dependent manner, stabilizing these transcripts and facilitating protein heterodimerization.
• FZD1/7 stabilization leads to β-catenin pathway activation, evidenced by enhanced nuclear translocation of non-phosphorylated β-catenin (Ser37/Thr41), promoting CSC stemness and survival.
• RBM15-driven m6A modification is necessary for IGF2BP3 recognition of FZD1/7, highlighting a broader regulatory network in RNA methylation and protein-RNA interactions.
• Genetic or pharmacological inhibition of IGF2BP3 or FZD1/7 disrupts CSC maintenance, impairs homologous recombination repair, and sensitizes cells to carboplatin.
• The small molecule Fz7-21, when combined with carboplatin, synergistically inhibits CSC survival and overcomes established resistance phenotypes.

Together, these insights suggest that targeting the IGF2BP3–FZD1/7 signaling axis could reduce the required dosage of platinum-based DNA synthesis inhibitors, potentially improving clinical outcomes and minimizing toxicity for TNBC patients undergoing carboplatin-based chemotherapy.

Comparison with Existing Internal Articles

The findings from Cai et al. integrate and extend several themes found in recent translational oncology literature. For example, "Redefining Platinum-Based Chemotherapy: Mechanistic Insights…" contextualizes how the IGF2BP3–FZD1/7 axis mediates CSC-driven chemoresistance and highlights the need for experimental designs that combine DNA synthesis inhibitors with stemness-targeted agents. Similarly, "Next-Generation Cancer Research: Harnessing Carboplatin and Stemness Inhibition…" discusses the rationale for integrating platinum-based agents such as carboplatin with inhibitors of stemness pathways, underscoring the translational value of combinatorial strategies. These internal resources reinforce the clinical urgency and experimental tractability of disrupting CSC maintenance as a route to overcoming chemoresistance in TNBC and other malignancies.

Distinct from prior work, the current study maps direct molecular interactions between IGF2BP3 and FZD1/7, providing a structural basis for developing next-generation inhibitors targeting RNA-protein complexes—thus offering new avenues for rational drug design and biomarker development in cancer research workflows.

Limitations and Transferability

While the reference study offers compelling preclinical evidence, several limitations merit consideration. First, the work primarily utilizes cellular models and ex vivo assays; in vivo validation, including xenograft models and assessment of long-term tumor recurrence, would strengthen translational relevance. Second, the study focuses on TNBC, and the generalizability of the IGF2BP3–FZD1/7 axis to other cancer subtypes remains to be determined. Third, while m6A-dependent regulation emerges as a central mechanism, the broader interactome and potential compensatory pathways in clinical samples require further elucidation. Finally, the long-term safety, pharmacodynamics, and clinical efficacy of FZD1/7-targeted agents—in combination with carboplatin—necessitate rigorous investigation before clinical translation.

Research Support Resources

Researchers aiming to replicate or extend these findings can leverage robust platinum-based DNA synthesis inhibitors for preclinical oncology research. Carboplatin (SKU A2171) is widely used in cell proliferation and cytotoxicity assays, and its mechanism—covalent DNA binding and repair inhibition—directly intersects with the homologous recombination pathways explored in the reference study. As discussed in both the internal review and the current study, integrating carboplatin with molecular inhibitors of stemness (such as Fz7-21) offers a rational approach to dissecting resistance mechanisms and optimizing experimental models in TNBC. For experimental protocols, carboplatin is typically stored as a solid at -20°C, is water-soluble with gentle warming, and is commonly applied in both monotherapy and combination regimens to interrogate cancer cell proliferation, DNA repair, and therapeutic synergy. APExBIO provides detailed technical guidance to support these workflows.